ITRM Logo

Iterum Therapeutics plc (ITRM) 

NASDAQ
Market Cap
$28.04M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
232 of 776
Rank in Industry
134 of 433

Largest Insider Buys in Sector

ITRM Stock Price History Chart

ITRM Stock Performance

About Iterum Therapeutics plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Insider Activity of Iterum Therapeutics plc

Over the last 12 months, insiders at Iterum Therapeutics plc have bought $109,995 and sold $0 worth of Iterum Therapeutics plc stock.

On average, over the past 5 years, insiders at Iterum Therapeutics plc have bought $74,998 and sold $12.8M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Dunne Michael W. (director) — $94,132. Fishman Corey N. (Chief Executive Officer) — $15,863.

The last purchase of 25,000 shares for transaction amount of $35,000 was made by Dunne Michael W. (director) on 2023‑12‑22.

List of Insider Buy and Sell Transactions, Iterum Therapeutics plc

2023-12-22Purchasedirector
25,000
0.1716%
$1.40$35,000+1.43%
2023-12-18Purchasedirector
10,000
0.0794%
$1.84$18,442-18.47%
2023-11-22Purchasedirector
20,000
0.1507%
$2.03$40,690-29.81%
2023-11-20PurchaseChief Executive Officer
10,000
0.0872%
$1.59$15,863+5.38%
2022-12-02SaleChief Medical Officer
3,365
0.0261%
$1.32$4,442-23.02%
2022-03-14SaleChief Financial Officer
63,340
0.029%
$0.31$19,635-62.16%
2022-03-11SaleChief Financial Officer
47,132
0.0261%
$0.38$17,910-61.07%
2021-02-12Sale10 percent owner
10.62M
8.7758%
$2.27$24.11M-69.11%
2021-02-11Sale10 percent owner
10M
9.0673%
$2.59$25.9M-70.30%
2021-01-26SalePresident & CEO
170,890
0.077%
$0.86$147,820-49.75%
2021-01-26Saledirector
33,143
0.0299%
$1.73$57,337-49.75%
2021-01-26SaleChief Financial Officer
33,868
0.0305%
$1.73$58,592-49.75%
2020-10-27PurchaseChief Scientific Officer
123,080
0.3428%
$0.33$40,001+124.28%
2020-09-30SaleChief Financial Officer
112,260
0.3651%
$0.82$92,053+5.71%
2020-06-02Sale10 percent owner
800,000
2.5418%
$0.80$642,960-32.10%
2020-06-01Sale10 percent owner
200,000
0.6371%
$0.85$169,120-35.29%
2018-11-30Purchasedirector
20,000
0.1148%
$3.14$62,887+2.19%
2018-10-30Purchasedirector
116,000
1.3004%
$6.10$707,600+3.21%
2018-09-04PurchaseChief Scientific Officer
1,000
0.0038%
$5.00$5,000-30.64%
2018-08-27PurchaseChief Scientific Officer
1,000
0.0071%
$10.00$10,000-34.86%

Insider Historical Profitability

124.28%
Dunne Michael W.director
113754
0.501%
$1.2481+124.28%
Fishman Corey N.Chief Executive Officer
54449
0.2398%
$1.2431
Ahrens Brenton Karldirector
1733170
7.6331%
$1.2410
CANAAN X L.P.
1733170
7.6331%
$1.2410
HEALY JAMES
1726514
7.6038%
$1.2410

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.